相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study
Paolo Denti et al.
CLINICAL INFECTIOUS DISEASES (2022)
Treatment and Outcome in Children With Tuberculous Meningitis: A Multicenter Pediatric Tuberculosis Network European Trials Group Study
Stephanie Thee et al.
CLINICAL INFECTIOUS DISEASES (2022)
Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios
Hannah Yejin Kim et al.
THERAPEUTIC DRUG MONITORING (2022)
One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation
Paolo Denti et al.
LANCET CHILD & ADOLESCENT HEALTH (2022)
Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
Rovina Ruslami et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2022)
Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations
Chishala Chabala et al.
CLINICAL INFECTIOUS DISEASES (2022)
Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial
Mandar S. Paradkar et al.
CLINICAL INFECTIOUS DISEASES (2022)
Population pharmacokinetics of ethambutol in African children: a pooled analysis
Tjokosela Tikiso et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)
Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
A. Turkova et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies
Alaa Bahaa Eldeen Soliman et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2022)
Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study
Daniel Van Aartsen et al.
LANCET MICROBE (2022)
Clinical standards for the dosing and management of TB drugs
J. W. C. Alffenaar et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2022)
Treatment Outcomes of Childhood Tuberculous Meningitis in a Real-World Retrospective Cohort, Bandung, Indonesia
Heda M. Nataprawira et al.
EMERGING INFECTIOUS DISEASES (2022)
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
S. E. Dorman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment
Renu Verma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial
Anthony J. Garcia-Prats et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis
Jan-Willem C. Alffenaar et al.
CLINICAL INFECTIOUS DISEASES (2020)
Pharmacokinetics of isoniazid in children with tuberculosis-A comparative study at two doses
Ira Shah et al.
PEDIATRIC PULMONOLOGY (2020)
Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania
Museveni Justine et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2020)
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
Tom G. Jacobs et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Adolescent tuberculosis
Kathryn J. Snow et al.
LANCET CHILD & ADOLESCENT HEALTH (2020)
Pharmacokinetics of isoniazid in Indian children with tuberculosis on daily treatment
I. Shah et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2019)
Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands
Fajri Gafar et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs
Alper Daskapan et al.
CLINICAL PHARMACOKINETICS (2019)
Protein binding of rifampicin is not saturated when using high-dose rifampicin
Carlijn H. C. Litjens et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Protein Binding of First-Line Antituberculosis Drugs
Wael A. Alghamdi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status
Rajeshwar Dayal et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2018)
The incidence of tuberculosis among adolescents and young adults: a global estimate
Kathryn J. Snow et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India
Jaya Ranjalkar et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children
Lisa C. Martial et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
K. E. Stott et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
Marjorie Z. Imperial et al.
NATURE MEDICINE (2018)
Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection
Sampson Antwi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis
Vidya Mave et al.
PLOS ONE (2017)
Understanding PK/PD
Jason A. Roberts et al.
INTENSIVE CARE MEDICINE (2016)
Naive-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis
Thomas Pouplin et al.
BMC INFECTIOUS DISEASES (2016)
A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children
Alessandro Schipani et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests
Soumya Swaminathan et al.
CLINICAL INFECTIOUS DISEASES (2016)
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children
A. Mukherjee et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2016)
Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes
H. McIlleron et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Rayyan-a web and mobile app for systematic reviews
Mourad Ouzzani et al.
SYSTEMATIC REVIEWS (2016)
Exposure to Total and Protein-Unbound Rifampin Is Not Affected by Malnutrition in Indonesian Tuberculosis Patients
L. H. M. te Brake et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
Aparna Mukherjee et al.
BMC INFECTIOUS DISEASES (2015)
Antituberculosis Drugs in Children
H. S. Schaaf et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme, India, 2009
A. Arya et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2015)
Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement
Lesley A. Stewart et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol
R. Mlotha et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Pharmacokinetics of First-Line Antituberculosis Drugs in HIV-Infected Children with Tuberculosis Treated with Intermittent Regimens in India
Geetha Ramachandran et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Pharmacokinetics of isoniazid in Ethiopian children with tuberculosis in relation to the N-acetyltransferase 2 (NAT2) genotype
Misgana Ibrahim
African Journal of Pharmacy and Pharmacology (2014)
Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis
Silvia S. Chiang et al.
LANCET INFECTIOUS DISEASES (2014)
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
Junichi Azuma et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children
G. Ramachandran et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2013)
Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy
Jotam G. Pasipanodya et al.
CLINICAL INFECTIOUS DISEASES (2012)
Blood levels of pyrazinamide in children at doses administered under the revised national tuberculosis control program
V. Roy et al.
INDIAN PEDIATRICS (2012)
Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations
L. M. Verhagen et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2012)
Pharmacokinetics of Isoniazid, Rifampin, and Pyrazinamide in Children Younger than Two Years of Age with Tuberculosis: Evidence for Implementation of Revised World Health Organization Recommendations
S. Thee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
PYRAZINAMIDE PLASMA CONCENTRATIONS IN YOUNG CHILDREN WITH TUBERCULOSIS
Helen McIlleron et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2011)
Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults
Eva Fernandez et al.
Pharmaceutics (2011)
Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations
Marc Weiner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
A systematic review of pharmacokinetics studies in children with protein-energy malnutrition
Kazeem A. Oshikoya et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis
Hendrik Simon Schaaf et al.
BMC MEDICINE (2009)
Isoniazid Plasma Concentrations in a Cohort of South African Children with Tuberculosis: Implications for International Pediatric Dosing Guidelines
Helen McIlleron et al.
CLINICAL INFECTIOUS DISEASES (2009)
Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses
Pooja Gupta et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Development of a WHO growth reference for school-aged children and adolescents
Mercedes de Onis et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2007)
Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection
SM Graham et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Isoniazid pharmacokinetics in children treated for respiratory tuberculosis
HS Schaaf et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2005)
Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis
M Zhu et al.
PHARMACOTHERAPY (2002)
分享论文
